Published in Pulm Med on October 17, 2012
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer | NCT01185639
Radiotherapy for Oligometastatic Lung Cancer. Front Oncol (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA (2010) 10.97
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol (2000) 9.76
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Oligometastases. J Clin Oncol (1995) 4.95
Liver resection for colorectal metastases. J Clin Oncol (1997) 4.88
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol (2009) 4.59
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg (1997) 4.47
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist (2009) 3.92
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol (2007) 3.91
Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) (2007) 3.46
Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol (2011) 3.12
Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol (2009) 3.00
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol (2011) 2.92
Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys (1999) 2.84
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer (2009) 2.77
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.57
The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29
Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol (2010) 2.17
Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine (2007) 2.16
Engaging the vascular component of the tumor response. Cancer Cell (2005) 2.05
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol (2008) 1.97
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med (2008) 1.79
Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys (2006) 1.66
Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol (2006) 1.58
Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol (2006) 1.56
Importance of local control in an era of systemic therapy. Nat Clin Pract Oncol (2005) 1.47
Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys (2008) 1.46
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol (2011) 1.46
MicroRNA expression characterizes oligometastasis(es). PLoS One (2011) 1.45
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol (2012) 1.31
Pain control by image-guided radiosurgery for solitary spinal metastasis. J Pain Symptom Manage (2008) 1.25
Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. J Neurosurg (1995) 1.19
Stereotatic radiosurgery of 468 brain metastases < or =2 cm: implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys (2004) 1.18
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol (2007) 1.15
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol (2004) 1.09
Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer (2012) 1.08
Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. Int J Radiat Oncol Biol Phys (2008) 1.07
Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol (2009) 1.07
Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. Eur J Cardiothorac Surg (2004) 1.07
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol (2013) 1.03
Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. Radiat Oncol (2011) 0.98
Risk factors affecting survival after brain metastases from non-small cell lung carcinoma: a follow-up study of 70 patients. J Neurosurg (2001) 0.93
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol (2012) 0.91
Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. Lung Cancer (2003) 0.90
Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. Lung Cancer (2006) 0.88
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol (2011) 0.87
Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases. Clin Lung Cancer (2012) 0.87
Stage III non-small cell lung cancer and metachronous brain metastases. J Thorac Cardiovasc Surg (2002) 0.84
Treatment of brain metastases from primary lung cancer. Int J Radiat Oncol Biol Phys (1995) 0.83
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer (2004) 4.54
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol (2007) 3.91
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys (2010) 3.66
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys (2011) 2.36
Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys (2013) 2.35
ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil. Head Neck (2012) 2.07
Palliative radiotherapy for prostate cancer. Oncology (Williston Park) (2014) 2.05
The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol (2007) 1.98
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol (2010) 1.90
The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol (2007) 1.67
Small cell lung cancer: have we made any progress over the last 25 years? Oncologist (2007) 1.62
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.62
ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. Oral Oncol (2011) 1.45
MicroRNA expression characterizes oligometastasis(es). PLoS One (2011) 1.45
Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys (2011) 1.28
Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol (2009) 1.27
Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg (2010) 1.26
A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol (2008) 1.24
A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol (2009) 1.16
Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. Int J Radiat Oncol Biol Phys (2012) 1.13
Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. Int J Radiat Oncol Biol Phys (2008) 1.07
Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys (2011) 1.07
Tumor necrosis and cavitation after stereotactic body radiation therapy. J Thorac Oncol (2010) 1.06
Abscopal effect of radiation on toruliform para-aortic lymph node metastases of advanced uterine cervical carcinoma--a case report. Anticancer Res (2007) 1.04
Calculation and prediction of the effect of respiratory motion on whole breast radiation therapy dose distributions. Med Dosim (2008) 1.03
Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report. J Med Case Rep (2011) 1.02
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. Head Neck (2010) 0.99
Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Neurosurgery (2013) 0.99
Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer (2008) 0.99
Local control and toxicity outcomes in brainstem metastases treated with single fraction radiosurgery: is there a volume threshold for toxicity? J Neurooncol (2014) 0.98
Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists. Am J Clin Oncol (2017) 0.97
How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems. J Thorac Oncol (2011) 0.96
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer (2011) 0.95
The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg (2012) 0.94
Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. J Neurooncol (2012) 0.93
Insufficiency fractures after pelvic radiation therapy for uterine cervical cancer: an analysis of subjects in a prospective multi-institutional trial, and cooperative study of the Japan Radiation Oncology Group (JAROG) and Japanese Radiation Oncology Study Group (JROSG). Int J Radiat Oncol Biol Phys (2012) 0.92
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. Am J Clin Oncol (2011) 0.92
Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. World J Urol (2014) 0.91
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol (2012) 0.91
Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases. Pulm Med (2012) 0.91
Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer. Radiother Oncol (2006) 0.89
Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg (2009) 0.87
Toxicity of gamma knife radiosurgery in the treatment of intracranial tumors in patients with collagen vascular diseases or multiple sclerosis. Int J Radiat Oncol Biol Phys (2011) 0.87
Clinical outcomes of brain metastases treated with Gamma Knife radiosurgery with 3.0 T versus 1.5 T MRI-based treatment planning: have we finally optimised detection of occult brain metastases? J Med Imaging Radiat Oncol (2012) 0.86
Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol (2010) 0.86
A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol (2013) 0.86
Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer. Pulm Med (2012) 0.86
Stereotactic body radiotherapy: a critical review for nonradiation oncologists. Cancer (2013) 0.85
Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg (2010) 0.83
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol (2010) 0.83
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol (2011) 0.83
Local failure in resected N1 lung cancer: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys (2011) 0.83
Chemoradiation for patients with large-volume laryngeal cancers. Head Neck (2011) 0.83
Adaptive stereotactic body radiation therapy planning for lung cancer. Int J Radiat Oncol Biol Phys (2013) 0.83
Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol Cancer Res Treat (2013) 0.83
Stereotactic body radiation therapy for treatment of primary and metastatic pulmonary malignancies. Surg Oncol Clin N Am (2013) 0.82
Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer. Jpn J Clin Oncol (2010) 0.82
Erratum. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys (2016) 0.82
Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management. Cancer J (2016) 0.81
The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol (2012) 0.81
American College of Radiology Appropriateness Criteria(®) treatment of stage I T1 glottic cancer. Head Neck (2013) 0.80
Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. Int J Radiat Oncol Biol Phys (2011) 0.80
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer (2011) 0.80
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys (2005) 0.80
Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. J Thorac Oncol (2014) 0.80
When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis. Chest (2014) 0.79
Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. Lung Cancer (2013) 0.79
Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer. Gynecol Oncol (2002) 0.79
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol (2012) 0.79
Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men. Int J Radiat Oncol Biol Phys (2003) 0.78
Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium. Clin Lung Cancer (2013) 0.78
Reirradiation for recurrent head and neck cancer. Expert Rev Anticancer Ther (2012) 0.78
Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. Pulm Med (2012) 0.78
Quality assurance in the prospective multi-institutional trial on definitive radiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer: the individual case review. Jpn J Clin Oncol (2009) 0.78
Diffusion-weighted imaging for head and neck squamous cell carcinoma: quantifying repeatability to understand early treatment-induced change. AJR Am J Roentgenol (2014) 0.77
Multimodality surgical and hyperbaric management of mandibular osteoradionecrosis. Int J Radiat Oncol Biol Phys (2009) 0.76
"The best-laid plans ... often go awry ...". J Thorac Oncol (2009) 0.76
Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy. Oral Oncol (2013) 0.76
High-dose-rate intra-cavitary brachytherapy combined with external beam radiation therapy for under 40-year-old patients with invasive uterine cervical carcinoma: clinical outcomes in 118 Patients in a Japanese multi-institutional study, JASTRO. Jpn J Clin Oncol (2013) 0.76
Contemporary radiotherapy in head and neck cancer: balancing chance for cure with risk for complication. Surg Oncol Clin N Am (2013) 0.76
Reply, contralateral irradiation for T(limited)N2bM0 lateralized tonsil cancer. Head Neck (2013) 0.75
Could it be that less is more? Lancet Oncol (2009) 0.75
A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Am J Clin Oncol (2007) 0.75
Advances in radiotherapy for tumors involving the mediastinum. Thorac Surg Clin (2009) 0.75
Treatment-induced changes in vocal cord mobility and subsequent local recurrence after organ preservation therapy for laryngeal carcinoma. Head Neck (2011) 0.75
Simple technique to visualize random set-up displacements using a commercially available radiotherapy planning system. Radiat Med (2005) 0.75
The radiotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer. J Radiat Res (2011) 0.75
Radiation safety issues with positron-emission/computed tomography simulation for stereotactic body radiation therapy. J Appl Clin Med Phys (2008) 0.75
Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol (2007) 0.75
Cost comparison of curative therapies for localized prostate cancer in Japan: a single-institution experience. Jpn J Radiol (2009) 0.75
Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer. Int J Clin Oncol (2011) 0.75
Treatment of Thymoma-Associated Myasthenia Gravis With Stereotactic Body Radiotherapy: A Case Report. Ann Intern Med (2016) 0.75